Journal
JOURNAL OF IMMUNOLOGY
Volume 197, Issue 1, Pages 108-118Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1501264
Keywords
-
Categories
Funding
- Higher Education Authority of Ireland
- Lee Kong Chian School of Medicine
- Nanyang Technological University
- Ministry of Education Singapore Academic Research Fund Tier 1 [2014-T1-001-141]
Ask authors/readers for more resources
In this study, we report that the integrin LFA-1 cross-linking with its ligand ICAM-1 in human PBMCs or CD4(+) T cells promotes Th1 polarization by upregulating IFN-gamma secretion and T-bet expression. LFA-1 stimulation in PBMCs, CD4(+) T cells, or the T cell line HuT78 activates the Notch pathway by nuclear translocation of cleaved Notch1 intracellular domain (NICD) and upregulation of target molecules Hey1 and Hes1. Blocking LFA-1 by a neutralizing Ab or specific inhibition of Notch1 by a gamma-secretase inhibitor substantially inhibits LFA-1/ICAM-1 mediated activation of Notch signaling. We further demonstrate that the Notch pathway activation is dependent on LFA-1/ICAM-1 induced inactivation of glycogen synthase kinase 313 (GSK3 beta,which is mediated via Akt and ERK. Furthermore, in silico analysis in combination with coimmunoprecipitation assays show an interaction between NICD and GSK3 beta. Thus, there exists a molecular cross-talk between LFA-1 and Notch1 through the Akt/ERK-GSK3 beta signaling axis that ultimately enhances T cell differentiation toward Th1. Although clinical use of LFA-1 antagonists is limited by toxicity related to immunosuppression, these findings support the concept that Notch inhibitors could be attractive for prevention or treatment of Th1-related immunologic disorders and have implications at the level of local inflammatory responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available